Biospecifics Technologies Corp (BSTC): Toby Wegman , director of Biospecifics Technologies Corp sold 3,605 shares on Sep 13, 2016. The Insider selling transaction was reported by the company on Sep 13, 2016 to the Securities and Exchange Commission. The shares were sold at $37.54 per share for a total value of $135,349.72 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 13, 2016, Thomas Wegman (President) sold 3,605 shares at $37.54 per share price.On Sep 2, 2016, Toby Wegman (President) sold 9,201 shares at $37.52 per share price.Also, On Dec 22, 2015, Jeffrey Kenneth Vogel (other) purchased 11,196 shares at $48.39 per share price.On Jul 21, 2015, Paul Gitman (director) sold 8,692 shares at $53.00 per share price.
BioSpecifics Technologies Corp.: On Monday, Sep 12, 2016 heightened volatility was witnessed in BioSpecifics Technologies Corp. which led to swings in the share price. The shares opened for trading at $36.18 and hit $37.35 on the upside , eventually ending the session at $37.28, with a gain of 2.03% or 0.74 points. The heightened volatility saw the trading volume jump to 28,103 shares. The 52-week high of the share price is $63.195 and the company has a market cap of $261 M . The 52-week low of the share price is at $30.7.
BioSpecifics Technologies Corp. is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals Inc. (Auxilium) for injectable collagenase for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an option to acquire additional indications that the Company may pursue including human and canine lipoma. The Company generates revenue primarily from Auxilium pursuant to the Second Amended and Restated Development and License Agreement with Auxilium (Auxilium Agreement). Under the Auxilium Agreement the Company receives license sublicense income royalties milestones and mark-up on cost of goods sold payments related to the sale and approval of XIAFLEX.